Portugal - English - HMA (Heads of Medicines Agencies)

cyton biosciences ltd - colistin sulfate 0 iu/ml - oral solution - cattle young, chicken, other young, pigs - colistin

Romania - English - HMA (Heads of Medicines Agencies)

cyton biosciences ltd - colistin sulfate 0 iu/ml - oral solution - cattle young, chicken, other young, pigs - colistin

United Kingdom - English - HMA (Heads of Medicines Agencies)

cyton biosciences ltd - colistin sulfate 0 iu/ml - oral solution - cattle young, chicken, other young, pigs - colistin

Ireland - English - HPRA (Health Products Regulatory Authority)

forest laboratories uk ltd - colistin sulfate - tablets - 1,500,000 international unit

Ireland - English - HPRA (Health Products Regulatory Authority)

forest laboratories uk ltd - colistin sulfate - syrup - 250,000 units/ml

Israel - English - Ministry of Health

m.p.vet ltd - colistin sulfate - powder for solution - colistin sulfate 1000 mg/g - treatment and metaphylaxis of gastrointestinal infections caused by non-invasive escherichia coli susceptible to colistin in broilers, turkey and pigs.the presence of the disease in the herd should be established before metaphylactic treatment.

Philippines - English - FDA (Food And Drug Administration)

avli biocare inc. - colistin , amoxicillin , attapulgite , neomycin , electroytes - oral suspension (raspberry flavor) - formulation: each ml contains: colistin ......... 25 iu amoxicillin (as trihydrate) ............ 1 mg neomycin (as sulfate) ................. 330 ug attapulgite ....... 1 mg potassium chloride ... 375 ug sodium chloride ........ 250 ug magnesium sulfate....... 75 ug

Ireland - English - HPRA (Health Products Regulatory Authority)

sp veterinaria, s.a. - colistin - solution for use in drinking water/milk - 4000000 international unit(s)/millilitre - colistin - cattle, chickens, pigs, sheep, turkeys - antibiotics

Australia - English - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - amikacin, quantity: 500 mg (equivalent: amikacin sulfate, qty 667.5 mg) - injection, solution - excipient ingredients: sulfuric acid; sodium metabisulfite; sodium citrate dihydrate; water for injections - amikacin sxp injection is indicated in the short-term treatment of serious infections caused by susceptible strains of gram negative bacteria (see microbiology).,staphylococcus aureus, including methicillin resistant strains, is the principal gram positive organism sensitive to amikacin.,the use of amikacin in the treatment of staphylococcal infections should be restricted to second line therapy, and should be confined to patients suffering from severe infections caused by susceptible strains of staphylococcus who have failed to respond or are allergic to other available antibiotics.,amikacin sxp injection is indicated in the treatment of neonatal sepsis when sensitivity testing indicates that other aminoglycosides cannot be used.,in certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin type drug maybe indicated because of the possibility of infections due to gram positive organisms such as streptococci or pneumococci. if concomitant treatment with a penicillin type drug is indicated, then the drugs should be administered separately because in vitro mixing of the two drugs causes inactivation of amikacin.,clinical studies have shown amikacin to be effective in treating bacteraemia, septicaemia including neonatal sepsis and serious infections of the respiratory tract, bones and joints, central nervous system, skin and skin structures (including those resulting from burns), intra-abdominal organs, postoperative infections and complicated and recurrent urinary tract infections, when caused by susceptible organisms.

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k) - polymyxin b 500000 [usp'u] - acute infections caused by susceptible strains of pseudomonas aeruginosa . polymyxin b sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and blood-stream caused by susceptible strains of ps. aeruginosa . it may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of ps. aeruginosa . it may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: h influenzae, specifically meningeal infections. escherichia coli, specifically urinary tract infections. aerobacter aerogenes, specifically bacteremia. klebsiella pneumoniae, specifically bacteremia. note: in meningeal infections, polymyxin b sulfate should be administered only by the intrathecal route. to reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin b and other antibacterial drugs, polymyxin b should be use